Dexcel Pharma Inc. today announced that the Food & Drug Administration (FDA) has approved PerioChip® (chlorhexidine gluconate – 2.5mg) for shipment and storage at controlled room temperature. This makes administering adjunctive therapy for periodontal disease easier than ever before, by enabling dental professionals to store the therapy close to hand in the operatory and to access it as needed.
To secure FDA approval, Dexcel Pharma made slight modifications to the PerioChip manufacturing process without altering the pharmacokinetics.
PerioChip is a small biodegradable chip containing chlorhexidine gluconate that is easily inserted into the periodontal pocket around the tooth. It dissolves naturally in the pocket over seven to 10 days, killing all bacteria and inhibiting the proliferation of perio-pathogenic bacteria. PerioChip’s active ingredient, chlorhexidine, is a gold-standard broad-spectrum antimicrobial agent. Patients can eat, drink, and brush their teeth as usual after treatment.
For more information, call Dexcel Pharma Inc or dial 1-866-periochip.